secwatch.observer — SEC 8-K summary
======================================

Issuer:     iBio, Inc. (IBIO)
CIK:        0001420720
Form:       8-K
Filed at:   2025-04-22T23:59:59+00:00
Accession:  0001420720-25-000020
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iBio licenses first-in-class anti-Activin E antibody from AstralBio for up to $28M in milestones
--------------------------------------------------------------------------------

- Upfront $750K credit applied toward option fee; total milestone payments up to $28M, payable in cash or stock.
- Antibody demonstrated fat-selective weight loss and synergy with GLP-1 in obese rodent model.
- iBio also amended AstralBio collaboration to add a fifth cardiometabolic target using its AI platform.
- AstralBio eligible for low to mid-single-digit sublicense fees on any sublicense proceeds.
- iBio solely responsible for all development, manufacturing, and commercialization worldwide.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420720/000142072025000020/0001420720-25-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420720/000142072025000020/ibio-20250421x8k.htm
  HTML page:      https://secwatch.observer/filing/0001420720-25-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer